Alkermes

Alkermes is a biopharmaceutical company that develops and commercializes medicines for people living with complex and difficult-to-treat psychiatric and neurological disorders. Its areas of focus include addiction, serious mental illness and sleep disorders, conditions that are frequently overlooked or stigmatised. The company maintains a portfolio of marketed medicines for chronic psychiatric and neurological disorders, alongside an investigational pipeline of candidates in the same therapeutic areas.

The work spans an integrated research and development strategy, from drug discovery through development capabilities, supported by a specialised commercial infrastructure. Its scientific approach is described as patient-inspired, with deep neuroscience expertise applied to the conditions it targets.

Alkermes states that its people, and their empathy for patients, families and caregivers, are its greatest strengths, and that it works with urgency to bring forward new treatment options. Collaboration is described as central to how the company operates, with core values underpinning its culture and an emphasis on valuing individuals and respecting each voice. The company has been recognised as an employer of choice in the biotechnology industry.